Zynerba Pharmaceuticals to Present at Two Upcoming Virtual Investor Conferences
Zynerba Pharmaceuticals (NASDAQ: ZYNE) announced that CEO Armando Anido will present at two virtual investor conferences: the HC Wainwright Virtual 22nd Annual Healthcare Conference on September 14, 2020, at 3:30 PM EDT, and the Cantor Global Virtual Healthcare Conference on September 15, 2020, at 1:20 PM EDT. Both presentations will be accessible through the Investor Relations page on Zynerba's website. The company specializes in transdermal cannabinoid therapies targeting rare neuropsychiatric disorders such as Fragile X syndrome and autism spectrum disorder.
- None.
- None.
DEVON, Pa., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Chief Executive Officer, Armando Anido will participate in two upcoming virtual investor conferences. Mr. Anido will present a company overview at the HC Wainwright Virtual 22nd Annual Healthcare Conference on Monday September 14, 2020 at 3:30PM EDT. He will also present at the 2020 Cantor Global Virtual Healthcare Conference on Tuesday September 15, 2020 at 1:20PM EDT. Both meetings are being held virtually, and live webcasts of the presentations will be accessible on the Investor Relations page of http://www.zynerba.com.
About Zynerba Pharmaceuticals, Inc.
Zynerba Pharmaceuticals is the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome, autism spectrum disorder, 22q11.2 deletion syndrome, and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies. Learn more at www.zynerba.com and follow us on Twitter at @ZynerbaPharma.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company’s current expectations. These and other risks are described in the Company’s periodic reports, including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at www.sec.gov. Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
Investor Contact
William Roberts, Vice President, Investor Relations and Corporate Communications
Zynerba Pharmaceuticals
484.581.7489
robertsw@zynerba.com
FAQ
When will Zynerba Pharmaceuticals present at the HC Wainwright Conference?
What is the date and time of Zynerba's presentation at the Cantor Global Conference?
Where can I watch Zynerba Pharmaceuticals' investor presentations?
What is the focus of Zynerba Pharmaceuticals' product development?
What disorders does Zynerba Pharmaceuticals aim to treat?
